PDE4A and chronic obstructive pulmonary disease: Phosphodiesterase-4 (PDE4) inhibition has an established role in the management of chronic obstructive pulmonary disease (COPD); roflumilast is an anti-inflammatory drug that prevents exacerbations in the subgroup of patients with a chronic bronchitis phenotype [1].